| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 24.6 | 30.3 |
| Profit before tax | -16.2 | -9.8 |
| Net income | -16.2 | -9.8 |
| EPS (diluted, $ a share) | $-0.39 | $-0.24 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -19.0% |
|---|---|
| Operating margin | -75.3% |
10-Q filed with the SEC, NASDAQ: RXST. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
RxSight, Inc.: key numbers
- Share price
- $5.30Close, Nov 16
- Market cap
- $222M
- Shares outstanding
- 41.93MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Ophthalmic GoodsSIC 3851
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from RxSight, Inc.
All →RxSight Financial Results
RxSight reported Q3 2026 revenue of $24.6 million, a 19% decrease year-over-year, primarily due to competitive pressures. The company highlighted a strengthened commercial leadership team and a $60 million cash infusion from its strategic collaboration with Alcon, ending the quarter with $254.7 million in cash and investments.
- Term
- 3 months
“Since I joined last quarter, the team has moved quickly and accomplished a great deal in a short period of time. We have strengthened our commercial organization and leadership, made progress across key long-term growth initiatives, and taken decisive actions to align our cost structure with our priorities. While there is more work ahead, we remain focused on execution. Based on our progress, I am confident we are positioning our company for long-term success.”
Aziz Mottiwala, President and Chief Executive Officer